3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
8
Neuroblastoma
4
Retinoblastoma
3
Fallopian Tube Neoplasms
3
Sarcoma, Ewing
2
Lung Neoplasms
2
Ganglioneuroblastoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Recurrence
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Glioma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Oxaliplatin
5
Mitomycin
4
Hyperthermic Intraperitoneal Chemotherapy
4
Fluorouracil
4
Cisplatin
4
Doxorubicin
3
Standard of Care
2
Paclitaxel
2
Leucovorin
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
sodium thiosulfate
1
relacorilant
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
X-Rays
1
Topotecan
1
Specimen Handling
1
Practice Guidelines as Topic
1
Platinum
1
Pancreatectomy
1
Pafolacianine
1
Observation
1
Mitozytrex
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Laparoscopy
1
LY-2157299
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Peritoneal Neoplasms
×
Topotecan
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled